Definitive Healthcare (NASDAQ:DH) Updates Q2 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its second quarter 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.030-0.040 for the period, compared to the consensus earnings per share estimate of 0.030. The company issued revenue guidance of $55.0 million-$56.0 million, compared to the consensus revenue estimate of $55.7 million. Definitive Healthcare also updated its FY 2026 guidance to 0.160-0.19 EPS.

Definitive Healthcare Trading Down 2.4%

NASDAQ:DH opened at $0.92 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.41. Definitive Healthcare has a 1-year low of $0.90 and a 1-year high of $4.70. The firm has a market capitalization of $97.23 million, a price-to-earnings ratio of -0.74, a PEG ratio of 82.60 and a beta of 1.34. The business’s 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.97.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, January 21st. Barclays lowered their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research note on Monday, March 30th. Canaccord Genuity Group cut their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday, February 27th. Finally, Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and an average price target of $3.27.

Key Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q1 results beat consensus: DH reported $0.06 EPS vs. a $0.03 consensus and revenue of $55.93M vs. ~$55.0M expected — a clean beat on both EPS and revenue, which supports near-term upside. Definitive Healthcare Corp. (DH) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised/updated guidance: FY2026 EPS guidance of $0.16–$0.19 (vs. consensus ~$0.14) and revenue guidance of $220–$226M (street ~$223.5M). Q2 EPS guidance of $0.03–$0.04 and revenue $55–$56M roughly track or slightly top consensus — these guidance ranges reinforce the beat and provide clarity on the outlook. Guidance Update (company release)
• Neutral Sentiment: Company hosted an earnings call / released the transcript and slides where management discussed results, growth drivers and execution plans — useful detail for longer-term investors but not a discrete catalyst beyond the numbers and guidance. Definitive Healthcare Corp. (DH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Company press release and slide deck provide supporting detail on revenue mix and initiatives; these materials confirm the numbers and guidance but introduce no surprising new guidance items. Definitive Healthcare Reports Financial Results for First Quarter 2026
• Negative Sentiment: Profitability and valuation remain concerns: the company still shows a negative net margin (~-57.5%) and a negative/low market-cap profile, keeping upside capped as investors demand sustained margin improvement. MarketBeat Q1 Summary
• Negative Sentiment: Guidance is a mixed signal: Q2 revenue lower bound ($55.0M) is slightly below consensus while the FY range spans the Street estimate — investors may view the range as cautious given recent volatility, which can limit enthusiasm. DH Q1 2026 Earnings Transcript

Institutional Trading of Definitive Healthcare

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its position in shares of Definitive Healthcare by 32.9% during the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock worth $72,000 after acquiring an additional 4,407 shares in the last quarter. Invesco Ltd. lifted its position in Definitive Healthcare by 5.8% in the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after acquiring an additional 6,400 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Definitive Healthcare in the 2nd quarter worth $32,000. Creative Planning boosted its stake in Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after purchasing an additional 8,428 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new position in Definitive Healthcare during the 4th quarter worth about $35,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.